The Fly | FBRX

Today

Forte Biosciences initiated with bullish view at Barclays, here's why

FBRX

4:47 AM

Over a week ago

First Tracks Biotherapeutics price target raised by $14 at H.C. Wainwright, here's why

Jul 10, 6:04 AM

What You Missed On Wall Street On Thursday

+24

Jul 9, 4:14 PM

Midday Fly By: PepsiCo reports mixed Q2, Levi Strauss posts 'beat and raise'

+25

Jul 9, 12:00 PM

Forte Biosciences trading resumes

FBRX

Jul 9, 9:42 AM

Forte Biosciences trading halted, volatility trading pause

FBRX

Jul 9, 9:32 AM

Forte Biosciences' FB102 shows efficacy in vitiligo Phase 1b study

FBRX

Jul 9, 8:06 AM

Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)

FBRX

May 11, 9:02 AM

Forte Biosciences 5.71M share Spot Secondary priced at $26.27

FBRX

Apr 8, 9:31 PM

Forte Biosciences announces common stock offering, no amount given

FBRX

Apr 8, 4:13 PM

Forte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year

FBRX

Mar 31, 4:01 PM

Forte Biosciences initiated with bullish view at Evercore ISI, here's why

FBRX

Nov 25, 6:34 AM

Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)

FBRX

Nov 14, 9:02 AM

Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

FBRX

Aug 18, 6:42 AM

Forte Biosciences initiated with bullish view at Guggenheim

FBRX

Aug 18, 6:10 AM

Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)

FBRX

Aug 14, 4:02 PM

Sixteen new option listings on July 23rd

Jul 23, 8:30 AM

No more stories

Novel Biotherapeutic Approach: Development of live biotherapeutic products for dermatological conditions offered a distinct mechanism targeting the skin microbiome, differentiating it from traditional small molecule or antibody treatments.

Targeting Underlying Pathology: Focused on addressing the fundamental dysbiosis and inflammatory pathways implicated in atopic dermatitis, rather than solely providing symptomatic relief.

Non-Systemic, Topical Delivery: The advantage of a topical formulation for its lead candidate reduced the risk of systemic side effects often associated with oral or injectable treatments for chronic conditions.

Clinical Trial Success Uncertainty: The success of their new lead candidate, FB-201, is highly uncertain, and previous program failures could recur, leading to further setbacks and potential program abandonment.

Significant Capital Requirements: Forte Biosciences requires substantial additional funding to complete the development and commercialization of FB-201, and future financing may not be available on favorable terms or at all, leading to dilution or an inability to continue operations.

Regulatory Approval Challenges: Obtaining regulatory approval for FB-201 is a complex, lengthy, and uncertain process, and failure to secure necessary approvals would prevent them from commercializing the product.

Charts

Targeting Underlying Pathology: Focused on addressing the fundamental dysbiosis and inflammatory pathways implicated in atopic dermatitis, rather than solely providing symptomatic relief.